SCHEMBL2897360

SCHEMBL2897360

C=Cc1cc2c(O[C@@H]3C[C@@H](C(=O)O)N(C(=O)O)C3)cc(-c3ccccc3)nc2cc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
ALDH1A1 P00352 2/20 0.37
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
DHODH Q02127 1/20 0.36
STING1 Q86WV6 1/20 0.35
EGFR P00533 2/20 0.35
ERBB2 P04626 2/20 0.35
PLA2G2A P14555 1/20 0.35
TRPV1 Q8NER1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1070891 0.90 MEN1 (0.40) SMN1; SMN2KDM4EMEN1KMT2ALMNA
SCHEMBL2892863 0.87 SMN1; SMN2 (0.40) SMN1; SMN2KDM4EMEN1KMT2ALMNA
SCHEMBL4541724 0.87 HTR3E (0.37) SMN1; SMN2KDM4EMEN1KMT2ALMNA
SCHEMBL12963581 0.85 MEN1 (0.39) SMN1; SMN2KDM4EMEN1KMT2ALMNA
SCHEMBL8213890 0.85 UCHL1 (0.43) SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL4556318 0.83 KDM4E (0.55) SMN1; SMN2KDM4EMEN1KMT2ALMNA
SCHEMBL3496077 0.83 STING1 (0.35) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL4531833 0.82 RXFP1 (0.46) MEN1KMT2ALMNAALDH1A1HTR3E
SCHEMBL2894467 0.81 AAK1 (0.35) AAK1
Hydrochloric Acid SCHEMBL2744132 0.80 SMN1; SMN2 (0.41) SMN1; SMN2KDM4EMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2083844-B1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2013-11-27 EP disclosed
US-8591878-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-11-26 US disclosed
US-8377874-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2013-02-19 US disclosed
US-20100286185-A1 HCV NS3 Protease Inhibitors MERCK SHARP & DOHME LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286185-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC SMN1; SMN2 4284/4885KDM4E 2747/4885MEN1 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.